Neurocrine (small cell) cancer of the prostate: an update

A new review article in the open access journal Oncology offers some key information about neuroendocrine (small-cell) carcinomas of the prostate (and why they offer essential lessons about the diagnosis and management of prostate cancer). … READ MORE …

What a young primary care opinion leader thinks about screening for prostate cancer

In a guest blog post, published yesterday on the MedPage Today web site, Dr. Andrew Buelt, a co-producer of the “Questioning Medicine” podcast for physicians, takes on the issue of screening for prostate cancer. … READ MORE …

Cancer screening re-visited again

An article by Melinda Beck in today’s issue of The Wall Street Journal discusses the complex topic of screening, “over-diagnosis”, and over-treatment of low-risk forms of certain cancers (prostate cancer specifically included). … READ MORE …

Metabolic aberrations and risk for prostate cancer

According to a newly published study of data from > 285,000 European males (the Metabolic Syndrome and Cancer Project), men with metabolic aberrations are at slightly less risk for a diagnosis of prostate cancer compared with men who have normal levels of metabolic factors … but their risk for prostate cancer-specific mortality is similar. … READ MORE …

How patients and others react to prostate cancer diagnosis and treatment

According to a media release issued earlier today by ZERO — The End of Prostate Cancer in conjunction with Ferring Pharmaceuticals Inc., “Prostate cancer impacts sex lives more than any other aspect of patients’ lives.” … READ MORE …

The less you know, the harder the decisions about treatment …

In one more of those utterly unsurprising research findings, a study of newly diagnosed patients has shown that poor patient knowledge about the nature of prostate cancer is associated with “decisional conflict” leading to stress and anxiety given the uncertainty associated with the relative “value” of the many possible management options. … READ MORE …

Results of the RADAR trial at 7.4 years of follow-up

The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,187 other followers